Piramal Pharma Q1 FY27: Loss Narrows, Revenue +17.4%

Key takeaway from Q1 FY27

Piramal Pharma Ltd. reported a narrower consolidated net loss for the first quarter of FY27, supported by double-digit revenue growth and a sharp improvement in operating profitability. For the quarter ended June 30, 2026, the company reported a consolidated net loss of ₹69.4 crore, compared with a loss of ₹81.7 crore in the same period last year. Revenue from operations rose 17.4% year-on-year to ₹2,270 crore, up from ₹1,934 crore a year earlier. The operating picture improved more sharply than the bottom line, with EBITDA nearly doubling year-on-year. The results were disclosed through the company’s quarterly earnings filing.

Revenue growth and what drove it

The company’s topline expansion in Q1 FY27 was attributed in the article to strong growth in the CDMO and hospital generics businesses. With revenue from operations at ₹2,270 crore, the growth rate stood at 17.4% year-on-year over ₹1,934 crore. The report also noted that the company expected the quarter’s revenue to benefit from a favourable INR depreciation of about 12-14% against the US dollar compared to Q1 FY26. Separately, the article referenced the Kenalog acquisition as another factor expected to contribute, describing it as a first full quarter contribution. These elements together frame the quarter as one where mix and currency tailwinds were supportive.

EBITDA surge and margin expansion

Operating performance improved significantly during the quarter. EBITDA jumped 82.9% to ₹195 crore, compared with ₹107 crore in the year-ago period. The EBITDA margin expanded to 8.6% from 5.5% in the corresponding quarter last year. The margin improvement was described as reflecting stronger operating leverage and improved profitability. While the company remained in a net loss position, the step-up in EBITDA indicates a sharper improvement at the operating level than at the reported profit level.

Net loss narrows despite still being in the red

Piramal Pharma’s consolidated net loss narrowed to ₹69.4 crore in Q1 FY27 from ₹81.7 crore in Q1 FY26. The article quantified the year-on-year reduction in loss at about 15.06%. This improvement aligned with the reported rise in revenue and the surge in EBITDA. Even with higher operating profitability, the quarter still ended with a loss, keeping focus on the pace at which operating gains translate into bottom-line recovery.

Operational updates: flooding disruption and US FDA clearance

The company highlighted that it was actively managing local operational disruptions, including a temporary suspension of its Ahmedabad facilities due to severe flooding. Alongside that near-term disruption, the article noted a regulatory milestone: successful US FDA clearance of its Sellersville facility in the United States. These updates matter because they speak to both execution risks (site disruptions) and compliance readiness (regulatory clearances) in a pharma and CDMO-heavy business.

Standalone performance mentioned in the filing

Beyond consolidated numbers, the article also provided standalone revenue from operations. Standalone revenue for the quarter stood at ₹1,124.95 crore, up from ₹969.88 crore in the corresponding quarter last year. The year-on-year standalone growth was stated at 15.99%. While standalone and consolidated numbers are not directly comparable, this disclosure offers another view of the company’s growth trajectory in the period.

Market snapshot and trading metrics cited

The article included several market and balance sheet indicators alongside the quarterly update. It cited a latest-quarter net debt figure of ₹4,296 crore. It also listed market cap at ₹24,197.23 crore and a current market price (CMP) of ₹181.75. In the same quick details section, it referenced the previous quarter’s revenue as ₹2,752 crore, previous quarter PAT as (₹9 crore), and previous quarter EBITDA margin as 18%. These figures provide context on recent quarter-to-quarter movement and market positioning.

Key numbers table

Market impact and why the quarter stands out

From a market perspective, the most notable shift in the quarter was the scale of operating improvement. Revenue growth of 17.4% year-on-year and EBITDA growth of 82.9% together pushed margins up by 310 basis points to 8.6%. The narrowing of the net loss to ₹69.4 crore from ₹81.7 crore indicates that operating gains helped absorb other costs, though profitability has not yet turned positive on a consolidated basis. The cited net debt of ₹4,296 crore adds balance sheet context, while the CMP of ₹181.75 and market cap of ₹24,197.23 crore frame how the market is valuing the business around this update.

What to watch next

The article also stated that the board would meet on July 29, 2026 to consider unaudited standalone and consolidated results for Q1 FY27. Operationally, investors are likely to track how quickly the company normalises operations following the temporary suspension of Ahmedabad facilities due to flooding. On the regulatory front, the US FDA clearance for the Sellersville facility is a datapoint that may matter for execution and compliance visibility in the company’s overseas operations.

Conclusion

Piramal Pharma’s Q1 FY27 results showed a narrower consolidated loss alongside strong revenue growth and a sharp EBITDA-led margin expansion. Near-term execution updates included flood-related disruption in Ahmedabad and a US FDA clearance for the Sellersville facility. With the company’s results dated July 29, 2026, the next set of disclosures and operational updates will be important for confirming the durability of the quarter’s margin improvement.